title: Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone.
abstract: Twenty-six in-patients with Diagnostic and Statistical Manual version IV (DSM-IV) criteria for opioid dependence were selected at random to receive either a combination of an 11-day low-dose buprenorphine and a 14-day carbamazepine regimen (n = 14) or a combination of an 11-day methadone and a 14-day carbamazepine regimen (n = 12) in a double-blind, randomized 14-day in-patient detoxification treatment. Patients with buprenorphine and carbamazepine showed a significantly better psychological state after the first and second weeks of treatment. Above all, the buprenorphine-treated patients demonstrated a less marked tiredness, sensitiveness and depressive state as well as a more prominent elevated mood during the detoxification process. Seven non-completers (after 7 days: four of 12 = 33.3%; after 14 days: seven of 12 = 58.3%) were treated with methadone and carbamazepine and five non-completers (after 7 days: two of 14 = 14.3%; after 14 days: five of 14 = 35.7%) received buprenorphine and carbamazepine. The difference in the overall dropout rate after day 14 was not significant. The present study supports the hypothesis that the combination of buprenorphine and carbamazepine leads to a better clinical outcome than does a combination of methadone and carbamazepine in the detoxification of opioid addicts with additional multiple drug abuse. The buprenorphine and carbamazepine-regimen provides a more effective short-term relief of affective disturbances than does methadone and carbamazepine. No severe side effects occurred during the treatment period in both groups.
authors.affiliation: Department of Clinical Psychiatry and Psychotherapy, Hannover Medical School, Germany. Seifert.Juergen@mh-hannover.de
authors.forename: J
authors.initials: J
authors.lastname: Seifert
authors.forename: C
authors.initials: C
authors.lastname: Metzner
authors.forename: W
authors.initials: W
authors.lastname: Paetzold
authors.forename: M
authors.initials: M
authors.lastname: Borsutzky
authors.forename: M
authors.initials: M
authors.lastname: Ohlmeier
authors.forename: T
authors.initials: T
authors.lastname: Passie
authors.forename: U
authors.initials: U
authors.lastname: Hauser
authors.forename: H
authors.initials: H
authors.lastname: Becker
authors.forename: B
authors.initials: B
authors.lastname: Wiese
authors.forename: Hm
authors.initials: H
authors.lastname: Emrich
authors.forename: U
authors.initials: U
authors.lastname: Schneider
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use; D002047:Buprenorphine / Q000008:administration & dosage / Q000627:therapeutic use*; D002220:Carbamazepine / Q000627:therapeutic use; D039721:Diagnostic and Statistical Manual of Mental Disorders; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006760:Hospitalization; D006801:Humans; D008658:Inactivation, Metabolic / Q000502:physiology*; D008297:Male; D008691:Methadone / Q000008:administration & dosage / Q000627:therapeutic use*; D019964:Mood Disorders / Q000175:diagnosis / Q000453:epidemiology* / Q000523:psychology; D009292:Narcotic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D009293:Opioid-Related Disorders / Q000175:diagnosis / Q000534:rehabilitation*
chemical_list: D000927:Anticonvulsants; D009292:Narcotic Antagonists; D002220:Carbamazepine; D002047:Buprenorphine; D008691:Methadone